Antibody Drug Conjugate (ADC) Markets, 2035
24 août 2023 06h33 HE
|
Research and Markets
Dublin, Aug. 24, 2023 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugate Market (7th Edition): Distribution by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens And Key...
Global Antibody Drug Conjugate (ADC) Forecast to 2028 - Next-Generation ADCs Spurring Growth Opportunities
22 août 2023 08h03 HE
|
Research and Markets
Dublin, Aug. 22, 2023 (GLOBE NEWSWIRE) -- The "Global Antibody Drug Conjugate (ADC) Growth Opportunities, Forecast to 2028" report has been added to ResearchAndMarkets.com's offering. The report...
ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
08 août 2023 07h00 HE
|
ADC Therapeutics SA
2Q 2023 ZYNLONTA®1 net sales increased 11% year-over-year; Implemented new go-to-market strategy during the quarter to support growth Operating expenses decreased 20%2 year-over-year due to portfolio...
ADC Therapeutics veranstaltet am 8. August 2023 eine Telefonkonferenz zu den Finanzergebnissen des zweiten Quartals 2023
01 août 2023 07h00 HE
|
ADC Therapeutics SA
LAUSANNE, Schweiz, Aug. 01, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) gab heute bekannt, dass es am Dienstag, den 8. August 2023, um 8:30 Uhr EDT eine Telefonkonferenz und einen...
ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
01 août 2023 07h00 HE
|
ADC Therapeutics SA
LAUSANNE, Switzerland, Aug. 01, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, August 8, 2023 at 8:30 a.m....
Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
24 juil. 2023 07h21 HE
|
ADC Therapeutics SA
BOSTON and SHANGHAI, China and LAUSANNE, Switzerland, July 24, 2023 (GLOBE NEWSWIRE) -- Overland ADCT BioPharma, a joint venture of Overland Pharmaceuticals (CY) Inc. and ADC Therapeutics SA (NYSE:...
ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
20 juil. 2023 16h05 HE
|
ADC Therapeutics SA
LAUSANNE, Switzerland, July 20, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it plans to discontinue the Phase 2 LOTIS-9 clinical trial evaluating ZYNLONTA®...
Global Cancer Antibody Drug Conjugates Market Outlook to 2029: Size, Drug Sales, Drug Dosage, Price, & Clinical Trials
16 juin 2023 06h28 HE
|
Research and Markets
Dublin, June 16, 2023 (GLOBE NEWSWIRE) -- The "Global Cancer Antibody Drug Conjugates Market Outlook 2029" report has been added to ResearchAndMarkets.com's offering.Global Cancer Antibody Drug...
ADC Therapeutics Announces Evolution of Board of Directors
15 juin 2023 07h15 HE
|
ADC Therapeutics SA
Strengthens the Board with the election of Robert W. Azelby as director Board will be comprised of nine directors; gratitude expressed for contributions of outgoing directors LAUSANNE,...
ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL
09 juin 2023 07h15 HE
|
ADC Therapeutics SA
LAUSANNE, Switzerland, June 09, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab...